Videos
Kidney Cancer
Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer.
Elizabeth Mittendorf, MD, PhD, director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, discusses the importance of identifying biomarkers in patients with breast cancer. Current studies are looking at PD-L1 as a possible biomarker, but Mittendorf believes there may be other biomarkers that will prove to be more reliable.
Prostate Cancer
Lawrence D. Wagman, MD, FACS, executive medical director of St. Joseph’s Hospital, discusses the future of precision medicine and genetic testing in the community.<br />
Catherine Fine, MS, Certified Genetic Counselor, lead, Clinical Cancer Services at Genome Medical, discusses questions on genetic counseling in the community setting.
Bridget F. Koontz, MD, associate professor of radiation oncology, Duke Cancer Institute, discusses a single-arm, phase II trial of 6 months of concurrent androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.
Approach to High-Risk Follicular Lymphoma
Hyman B. Muss, MD, professor of medicine, UNC Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill School of Medicine, discusses how he chooses which treatment to use for patients diagnosed with triple-negative breast cancer (TNBC).